5'-amino-2',5'-dideoxythymidine profile

5'-amino-2',5'-dideoxythymidine (AMT) is a nucleoside analog that has been studied for its potential as an antiviral agent. It is a chain terminator, inhibiting DNA polymerase by preventing further elongation. AMT is a potent inhibitor of human immunodeficiency virus (HIV) replication, and it has also shown activity against other viruses, such as herpes simplex virus (HSV) and cytomegalovirus (CMV). However, AMT's clinical development has been limited due to its toxicity. Research on AMT is ongoing, focusing on improving its therapeutic index by modifying its structure or delivery method.'

5'-amino-5'-deoxythymidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	65311
CHEMBL ID	319447
SCHEMBL ID	51992
MeSH ID	M0082006

Synonym
5'-amino-5'-deoxythymidine
25152-20-9
adthd
1-[(2r,4s,5r)-5-(aminomethyl)-4-hydroxy-tetrahydrofuran-2-yl]-5-methyl-pyrimidine-2,4-dione
5'-amino-5-deoxythymidine
5'-amino-5-methyl-2',5'-dideoxyuridine
1-((2r,4s,5s)-5-aminomethyl-tetrahydro-furan-2-yl)-5-methyl-2,4(1h,3h)-pyrimidinedione
5'-nh2-5-ch3-ddu
5'-nh2-2'-dt
1-((2r,4s,5r)-5-(aminomethyl)-4-hydroxy-tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1h,3h)-dione
1-((2r,5r)-5-aminomethyl-4-hydroxy-tetrahydro-furan-2-yl)-5-methyl-1h-pyrimidine-2,4-dione
5''-amino-5''-deoxythymidine
bdbm50132297
1-[(2r,4s,5r)-5-(aminomethyl)-4-hydroxyoxolan-2-yl]-5-methylpyrimidine-2,4-dione
CHEMBL319447 ,
5-addot
5'-amino-2',5'-dideoxythymidine
nsc 169339
SCHEMBL51992
PYWLBQPICCQJFF-XLPZGREQSA-N
5??-amino-5??-deoxythymidine
AKOS030530880
DTXSID30876098
1-((2r,4s,5r)-5-(aminomethyl)-4-hydroxytetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1h,3h)-dione
Q27455601
5'-amino-5'-deoxy-d-thymidine

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Thymidine kinase, cytosolic	Rattus norvegicus (Norway rat)	Ki	2.4000	2.4000	4.2000	6.5000	AID210886
Thymidylate kinase	Mycobacterium tuberculosis H37Rv	Ki	12.0000	4.5000	8.5000	10.0000	AID210904
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (22)

Assay ID	Title	Year	Journal	Article
AID126600	Affinity towards mitochondrial thymidine kinase relative to TdR.	1982	Journal of medicinal chemistry, Jun, Volume: 25, Issue:6	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID1131500	Antiviral activity against HSV1 at 400 uM	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Synthesis and biological activity of several amino analogues of thymidine.
AID1131501	Antineoplastic activity against mouse S180 cells at 400 uM	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Synthesis and biological activity of several amino analogues of thymidine.
AID125177	In vitro inhibitory activity against Moloney murine leukemia virus (M-MULV) replication, a mammalian T-lymphotropic retrovirus	1987	Journal of medicinal chemistry, Feb, Volume: 30, Issue:2	Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses.
AID210877	The compound was tested for inhibition of thymidine kinase using [3H]TMP as radioligand at concentration 50 uM in L1210 cells	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	A reappraisal of the effect upon thymidine kinase of thymidine derivatives carrying large groups at the 5'-position.
AID1145766	Cytotoxicity against African green monkey Vero cells assessed as inhibition of replication	1976	Journal of medicinal chemistry, Apr, Volume: 19, Issue:4	Synthesis and antiviral activity of 5- and 5'-substituted thymidine analogs.
AID210886	Competitive inhibition against rat cytoplasmic Thymidine kinase	1982	Journal of medicinal chemistry, Jun, Volume: 25, Issue:6	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID381854	Activity of Escherichia coli thymidine phosphorylase assessed as drug phosphorylation after 2 hrs	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Kinetic parameters and recognition of thymidine analogues with varying functional groups by thymidine phosphorylase.
AID1136939	Competitive inhibition of Escherichia coli B thymidine kinase using [2-14C]-thymidine as substrate assessed as formation of [14C]-TMP after 10 mins by Lineweaver-Burk double reciprocal plot analysis	1979	Journal of medicinal chemistry, Dec, Volume: 22, Issue:12	Design of species- or isozyme-specific enzyme inhibitors. 2. Differences between a bacterial and a mammalian thymidine kinase in the effect of thymidine substituents on affinity for the thymidine site.
AID210871	Thymidine kinase activity was measured by nonradiochemical assay method - TdR (percentage of the control rate measured in the absence of Tdr)	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	A reappraisal of the effect upon thymidine kinase of thymidine derivatives carrying large groups at the 5'-position.
AID152642	Cytotoxic effect in uninfected human peripheral blood mononuclear (PBM) cells	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.
AID210888	Affinity towards cytoplasmic Thymidine kinase relative ot TdR.	1982	Journal of medicinal chemistry, Jun, Volume: 25, Issue:6	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID381860	Activity of Escherichia coli thymidine phosphorylase assessed as drug phosphorylation after 1 hr	2008	Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7	Kinetic parameters and recognition of thymidine analogues with varying functional groups by thymidine phosphorylase.
AID233146	Differential affinity is the ratio between M-TK and C-TK	1982	Journal of medicinal chemistry, Jun, Volume: 25, Issue:6	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID210870	Thymidine kinase activity was measured by nonradiochemical assay method + TdR (percentage of the control rate measured in the presence of 5 uM Tdr)	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	A reappraisal of the effect upon thymidine kinase of thymidine derivatives carrying large groups at the 5'-position.
AID1131507	Antineoplastic activity against mouse L1210 cells at 400 uM	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Synthesis and biological activity of several amino analogues of thymidine.
AID126594	Competitive inhibition against rat mitochondrial thymidine kinase	1982	Journal of medicinal chemistry, Jun, Volume: 25, Issue:6	Species- or isozyme-specific enzyme inhibitors. 5. Differential effects of thymidine substituents on affinity for rat thymidine kinase isozymes.
AID210904	Inhibitory activity against thymidine monophosphate kinase (TMPK) in Mycobacterium tuberculosis	2003	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 13, Issue:18	Thymidine and thymidine-5'-O-monophosphate analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase.
AID1145767	Cytotoxicity against mouse Sarcoma 180 cells assessed as cell viability at 400 uM after 18 to 24 hrs relative to control	1976	Journal of medicinal chemistry, Apr, Volume: 19, Issue:4	Synthesis and antiviral activity of 5- and 5'-substituted thymidine analogs.
AID1145765	Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as viral titer at 400 uM after 40 hrs by plaque formation assay relative to control	1976	Journal of medicinal chemistry, Apr, Volume: 19, Issue:4	Synthesis and antiviral activity of 5- and 5'-substituted thymidine analogs.
AID210872	Thymidine kinase activity was measured by radio chemical assay method	1984	Journal of medicinal chemistry, Aug, Volume: 27, Issue:8	A reappraisal of the effect upon thymidine kinase of thymidine derivatives carrying large groups at the 5'-position.
AID154959	Antiviral activity against HIV I strain (LAV) in human peripheral blood mononuclear (PBM) cells	1989	Journal of medicinal chemistry, Mar, Volume: 32, Issue:3	Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	25 (71.43)	18.7374
1990's	7 (20.00)	18.2507
2000's	3 (8.57)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (2.86%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	34 (97.14%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
3-aminobenzamide [no description available]	1.98	1	benzamides; substituted aniline	EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor
thymidine [no description available]	5.46	21	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
idoxuridine [no description available]	4.86	11	organoiodine compound; pyrimidine 2'-deoxyribonucleoside	antiviral drug; DNA synthesis inhibitor
uridine [no description available]	2.66	3	uridines	drug metabolite; fundamental metabolite; human metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	3.06	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
cytidine [no description available]	1.96	1	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytarabine [no description available]	3.06	1	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
trifluridine Trifluridine: An antiviral derivative of THYMIDINE used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to HERPES SIMPLEX virus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p557). trifluridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis.	2.38	2	nucleoside analogue; organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; EC 2.1.1.45 (thymidylate synthase) inhibitor
phenyl isocyanate [no description available]	1.98	1	benzenes; isocyanates	allergen; hapten
fluorodeoxyuridylate Fluorodeoxyuridylate: 5-Fluoro-2'-deoxyuridylate. An inhibitor of thymidylate synthetase. Formed from 5-fluorouracil or 5-fluorodeoxyuridine.	2.01	1	pyrimidine 2'-deoxyribonucleoside 5'-monophosphate
5-fluorouridine [no description available]	2.01	1	organofluorine compound; uridines	mutagen
thymidine monophosphate Thymidine Monophosphate: 5-Thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety.. dTMP : The neutral species of thymidine 5'-monophosphate (2'-deoxythymidine 5'-monophosphate).	2.01	1	thymidine 5'-monophosphate	fundamental metabolite
deoxycytidine [no description available]	2.66	3	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxyuridine [no description available]	2.89	4	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
2-chloroethyl isocyanate [no description available]	1.96	1
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	2.66	3	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.	2.01	1	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	3.06	1	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	1.97	1	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
alovudine [no description available]	2.01	1	pyrimidine 2',3'-dideoxyribonucleoside
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	2.67	3	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
ribavirin Rebetron: Rebetron is tradename	3.06	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
fiacitabine fiacitabine: anti-herpes virus agent which also inhibits growth of certain human tumor cell lines in vitro.	3.06	1
3'-azido-2',3'-dideoxyuridine [no description available]	2.37	2
2',3'-dideoxycytidinene 2',3'-dideoxycytidinene: 2',3'-unsaturated derivative of 2',3'-dideoxycytidine; potent inhibitor of HTLV-III in vitro; structure given in first source	1.97	1
thymidine 5'-triphosphate thymidine 5'-triphosphate: RN given refers to parent cpd. dTTP : A thymidine phosphate having a triphosphate group at the 5'-position.	2.89	4	pyrimidine 2'-deoxyribonucleoside 5'-triphosphate; thymidine phosphate	Escherichia coli metabolite; mouse metabolite
3'-azido-2',3'-dideoxy-5-bromouridine 3'-azido-2',3'-dideoxy-5-bromouridine: a potent, selective inhibitor of HIV replication; a weak competitive inhibitor of thymidylate kinase	2.37	2
3'-azido-2',3'-dideoxy-5-methylcytidine 3'-azido-2',3'-dideoxy-5-methylcytidine: inhibits reproduction of AIDS virus in cultured cells	2.37	2
thymine arabinoside thymine arabinoside: selectively inhibits replication of herpes simplex virus	2.01	1	N-glycosyl compound
ibacitabine ibacitabine: antiherpetic agent	1.96	1	pyrimidine 2'-deoxyribonucleoside
methylthymidine methylthymidine: RN given refers to N-3-methylthymidine	1.96	1
2'-deoxyuridylic acid 2'-deoxyuridylic acid: RN given refers to parent cpd	2.01	1	deoxyuridine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-monophosphate	Escherichia coli metabolite; metabolite; mouse metabolite
2',3'-dideoxythymidine [no description available]	2.89	4
2',3'-didehydro-2',3'-dideoxyuridine [no description available]	2.37	2
2',3'-dideoxyuridine [no description available]	2.37	2	pyrimidine 2',3'-dideoxyribonucleoside
3'-azido-3'-deoxythymidine 5'phosphate 3'-azido-3'-deoxythymidine 5'phosphate: inhibits thymidylate kinase	2.01	1
5-chloro-2'-deoxyuridine [no description available]	1.98	1
edoxudin [no description available]	2.01	1	pyrimidine 2'-deoxyribonucleoside
4'-thiothymidine [no description available]	2.04	1
bromodeoxyuridylate bromodeoxyuridylate: RN given refers to parent cpd	2.01	1
cyanates Cyanates: Organic salts of cyanic acid containing the -OCN radical.. cyanates : Salts and esters of cyanic acid, HOC#N; compounds carrying the cyanate functional group -O-C#N.. isocyanates : Organonitrogen compounds that are derivatives of isocyanic acid; compounds containing the isocyanate functional group -N=C=O (as opposed to the cyanate group, -O-C#N).	2.38	2
3'-amino-2',3'-dideoxythymidine [no description available]	3.36	7
5-amino-2'-deoxyuridine 5-amino-2'-deoxyuridine: structure in first source	2.36	2
3'-amino-2',3'-dideoxyuridine 3'-amino-2',3'-dideoxyuridine: structure given in first source; a major metabolite of the antiviral agent, 3'-azido-2',3'-dideoxyuridine	1.97	1
5'-amino-5-iodo-2',5'-dideoxyuridine [no description available]	3.97	4
methotrexate [no description available]	1.97	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
2'-fluorothymidine [no description available]	2.01	1
n(3)-ethylthymidine N(3)-ethylthymidine: structure given in first source	1.95	1
3'-amino-3'-deoxythymidine 5'-monophosphate [no description available]	2.01	1
5,6-dihydrothymidine 5,6-dihydrothymidine: RN given refers to cpd without isomeric designation. 5,6-dihydrothymidine : A pyrimidine 2'-deoxyribonucleoside having dihydrothymine as the nucleobase.	1.96	1	pyrimidine 2'-deoxyribonucleoside	Mycoplasma genitalium metabolite
5-methyldeoxycytidine [no description available]	1.96	1	2'-deoxycytidine
brivudine brivudine: anti-herpes agent	3.06	1
5-iodo-2'-deoxyuridine 5'-monophosphate iododeoxyuridylate: RN given refers to parent cpd	2.01	1
3'-azido-2',3'-dideoxycytidine [no description available]	2.37	2
5-bromo-2',3'-dideoxyuridine 5-bromo-2',3'-dideoxyuridine: structure given in first source	1.97	1
5-cyano-2'-deoxyuridine 5-cyano-2'-deoxyuridine: structure in first source	1.95	1
sodium bicarbonate Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.	2.01	1	one-carbon compound; organic sodium salt	antacid; food anticaking agent
5-(1-propenyl)-2'-deoxyuridine 5-(1-propenyl)-2'-deoxyuridine: has anti-herpes activity; structure in first source	1.96	1
4'-thiothymidine 4'-thiothymidine: RN & structure given in first source	2.04	1
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	3.06	1	2-aminopurines; oxopurine	antimetabolite; antiviral drug

Condition	Relationship Strength	Studies
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	1.95	1
Sarcoma 180 An experimental sarcoma of mice.	2.36	2
Leukemia L 1210 [description not available]	2.65	3
HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.	1.97	1
Herpes Simplex Virus Infection [description not available]	1.96	1
Herpes Simplex A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.)	1.96	1
Furrow Keratitis [description not available]	1.96	1
Delayed Hypersensitivity [description not available]	1.96	1
Bladder Cancer [description not available]	2.67	3
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.67	3
Cancer of Colon [description not available]	1.99	1
Colonic Neoplasms Tumors or cancer of the COLON.	1.99	1
Carcinoma, Ehrlich Tumor A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.	2.01	1
Cancer of Skin [description not available]	1.98	1
Skin Neoplasms Tumors or cancer of the SKIN.	1.98	1

5'-amino-2',5'-dideoxythymidine

Description

Cross-References

Synonyms (26)

Protein Targets (3)

Inhibition Measurements

Bioassays (22)

Research

Studies (35)

Market Indicators

Research Demand Index: 10.48

Study Types

5'-amino-2',5'-dideoxythymidine

Description

Cross-References

Synonyms (26)

Protein Targets (3)

Inhibition Measurements

Bioassays (22)

Research

Studies (35)

Market Indicators

Research Demand Index: 10.48

Study Types

Related Drugs (60)

Related Conditions (15)